Jonathan Sporn
CEO and founder of Gilgamesh Pharma, with prior experience at Pfizer, Johnson & Johnson, and the NIH; led development of next-generation, short-acting psychedelic therapeutics and negotiated a lead asset deal with AbbVie.
Best podcasts with Jonathan Sporn
Ranked by the Snipd community
Mar 25, 2026 • 26min
How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics
Jonathan Sporn, CEO and founder of Gilgamesh Pharma and former Pfizer/J&J/NIH scientist, built next-gen short-acting psychedelic therapeutics. He discusses why shorter durations matter for real-world psychiatry. He explains designing molecules around clinical needs, trial design challenges, and how a data-driven approach led to a major AbbVie partnership.
